Pacific Biosciences at Jefferies Conference: Record Revenue and Strategic Shifts

At the Jefferies Global Healthcare Conference 2025, Pacific Biosciences (PACB) highlighted its strategic focus on long-read sequencing, reporting record consumable revenue exceeding $20 million in Q1 2024 and shipping 28 Vega systems, half to new customers in biopharma and microbiology. The company aims for positive cash flow by 2027 through restructuring, which includes pausing short-read sequencing development to prioritize long-read advancements and reduce annualized operating expenses by $45 million to $50 million. PacBio anticipates gross margin improvement, targeting over 40% by year-end, and sees significant growth potential in the germline human genetics market, including newborn screening initiatives and expansion in China.

Analysis

Pacific Biosciences of California (PACB) presented a focused strategy at the Jefferies Global Healthcare Conference, emphasizing its leadership in long-read sequencing technology. The company reported a record in consumable revenue, exceeding $20 million in Q1 2024, a positive indicator of system utilization and market adoption. Shipments of 28 Vega systems, with 50% to new customers in biopharma and microbiology, and 14 Revio systems in Q1 2024, despite a challenging capital environment, demonstrate initial market traction for its newer platforms. PacBio is undergoing a significant restructuring, aiming to reduce annualized operating expenses by $45 million to $50 million by pausing short-read sequencing development to concentrate resources on long-read advancements. This strategic pivot, coupled with operational improvements such as scaling Vega production, cost reductions in Revio systems through software enhancements (including removal of some NVIDIA GPUs), and the impact of Spark Chemistry (lowering DNA input and increasing data output by 46%), is geared towards achieving positive cash flow by 2027 and gross margins exceeding 40% by year-end 2025. The company sees substantial growth in germline human genetics, newborn screening (highlighted by the Thailand initiative), and biopharma markets, and aims to replace legacy short-read technologies. Expansion in China, via a new distributor HaoRe specializing in HLA and blood screening, proceeds without apparent negative impacts from scrutiny on American NGS products, with PacBio citing no current alternative to its HiFi sequencing in that market. While acknowledging the tough capital funding environment which affected previous guidance (low end reduced), management expressed optimism, citing strong European business and growing adoption in rare disease research.

Key Decisions for Investors

• Investors should closely monitor PacBio's progress in scaling Vega system production and achieving targeted gross margin improvements to over 40% by year-end, as these are critical for its path to profitability.
• Consider the implications of PacBio's strategic shift to exclusively focus on long-read sequencing, including its ability to penetrate the germline human genetics market and compete effectively against incumbents like Illumina, especially as Illumina also enters the long-read space.
• Evaluate the impact of the restructuring plan on operating expenses and the company's timeline to achieve positive cash flow by 2027, alongside continued consumable revenue growth which hit a record $20 million in Q1 2024.
• Assess the adoption rate of Spark chemistry and its contribution to increased data output and consumable sales, as well as the company's ability to navigate the challenging capital environment and maintain instrument sales momentum for both Vega and Revio systems.